Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial

Table 2 Percentage of patients with “no impairment” in representative CFQ-R items at baseline and 48 weeks

	Representative items			% No Impairment at baseline (pooled)
CFQ-R scale	Teen-adult version/Child version	Response option^a	Corr.^b with domain change score	% No Impairment at baseline (pooled)
Body image	Look different from others	Very false/Not at all true	0.82	60.0
Digestive symptoms	Problems with gas/stomach hurt	Never	0.85^c	48.1
Eating problems	Force myself to eat/pushed to eat	Very false/Never	0.82^c	77.7
Emotional functioning	Felt sad/worried	Never	0.79	71.1
Health perceptions	Feel healthy	Very true	0.86	32.5
Physical functioning	Walking as fast as others	No difficulty	0.85	65.9
Respiratory symptoms	Coughing	Not at all/Never	0.85	3.7
Role functioning	Running errands out of the house	Never	0.85	41.0
Social functioning	Comfortable going out/got together with friends	Very true	0.66	59.2
Treatment burden	Tx makes life more difficult/Tx bothered you	Not at all/Not at all true	0.78	25.1
Vitality	Felt exhausted/grouchy	Never	0.81	47.4
Weight^d	Trouble gaining weight	Not at all	^e	62.0

ISSN: 1477-7525